CAR-T cell

Phase 2Cell therapy

PPersonGen BioTherapeutics (Suzhou) Co., Ltd.

CAR-T cell is one of 223 small molecule programs targeting Systemic Lupus Erythematosus. It is currently in Phase 2.

Indications

Total Trials

Active Trials

222

Competitors

Pipeline

Status by Indication[3][1]

Indication

Systemic Lupus ErythematosusActive, not recruiting

Autoimmune DiseaseRecruiting

Diffuse Large B-Cell LymphomaRecruiting

Acute Myeloid LeukemiaRecruiting

MalignanciesWithdrawn

B-Cell Acute Lymphoblastic LeukemiaRecruiting

Systemic Lupus ErythematosusPreclinical

Active, not recruiting

Autoimmune DiseasePhase 2

Recruiting

Diffuse Large B-Cell LymphomaPhase 2

Recruiting

Acute Myeloid LeukemiaPhase 1

Recruiting

MalignanciesPhase 1

Withdrawn

B-Cell Acute Lymphoblastic LeukemiaPhase 1

Recruiting

Competition

Competitive Landscape

235 competitors in Acute Myeloid Leukemia

#DrugCompanyPhaseTrials

Idamycin

Pfizer

Phase 3

60 2

Novantrone

Pfizer

Phase 3

34 3

Xospata

Astellas

Phase 3

24 4

Fludara

Sanofi

Phase 3

18 5

Vepesid

AAvyxa

Phase 3

52 6

Mylotarg

WWyeth-Lederle Vaccines

Phase 3

38 7

Vanflyta

Daiichi Sankyo

Phase 3

16 8

Cerubidine

HHikma Pharmaceuticals LLC

Phase 3

32 9

Neupogen

EEastern Cooperative Oncology Group

Nexavar

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2027

Phase 1Recruiting

B-Cell Acute Lymphoblastic Leukemia

NCT04512716

Q4 2027

Phase 1Not yet recruiting

Autoimmune Disease

NCT06762119

N/ANot yet recruiting

Systemic Lupus Erythematosus

NCT06900764

Phase 1Recruiting

Malignancies

NCT07338604

Phase 1Recruiting

Hepatocellular Carcinoma

NCT05003895

Q2 2028

Phase 1Not yet recruiting

Autoimmune Disease

NCT07040917

Clinical

Trials by Indication[1]

Autoimmune Disease3 trials

A Study of CAR-T Cells in Subjects with Autoimmune Diseases

Not yet recruiting·ZZhejiang University·Phase 1·NCT06762119·6 enrolled

Anti-CD19 CAR T-Cell Therapy in Refractory Systemic Autoimmune Diseases

Recruiting·FFondazione Policlinico Universitario Agostino Gemelli IRCCS·Phase 1/2·NCT06685042·8 enrolled

A Study of CAR-T Cells in Subjects With Autoimmune Diseases

Not yet recruiting·—·Phase 1·NCT07040917·12 enrolled

Malignancies2 trials

A Phase I Trial of Donor- Derived 19-28z CAR T Cells Following Allogeneic Transplant for the Treatment of CD19 Malignancies

Withdrawn·MMemorial Sloan Kettering Cancer Center·Phase 1·NCT04556266

Clinical Study of UTAA07 Injection in the Treatment of Hematologic and Lymphatic Systemic Malignancies

Recruiting·PPersonGen BioTherapeutics (Suzhou) Co., Ltd.·Phase 1·NCT07338604·15 enrolled

Systemic Lupus Erythematosus1 trial

A Study of CAR-T Cells in Subjects With Systemic Lupus Erythematosus

Not yet recruiting·UUnion Hospital, Tongji Medical College, Huazhong University of Science and Technology·N/A·NCT06900764·24 enrolled

B-cell acute lymphoblastic leukemia1 trial

Iomab-ACT: A Pilot Study of 131-I Apamistamab Followed by CD19-Targeted CAR T-Cell Therapy for Patients With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia or Diffuse Large B-Cell Lymphoma

Recruiting·MMemorial Sloan Kettering Cancer Center·Phase 1·NCT04512716·12 enrolled

Nasopharyngeal Carcinoma1 trial

EBV CAR-T Cells for Nasopharyngeal Carcinoma

Unknown status·TThe Affiliated Hospital of Xuzhou Medical University·Phase 1·NCT05654077·24 enrolled

5 more indications

Lymphoblastic Lymphoma1 trial

Clinical Study of Anti-CD1a CAR-T in the Treatment of R/R Acute T-lymphoblastic Leukemia/Lymphoblastic Lymphoma

Unknown status·TThe Affiliated Hospital of Xuzhou Medical University·Phase 2·NCT05745181·20 enrolled

Diffuse Large B-Cell Lymphoma1 trial

Study of IOMAB-ACT Followed by CAR-T Cell Therapy for Patients Relapsed or Refractory (Diffuse Large B-cell Lymphoma

Recruiting·UUniversity of Texas Southwestern Medical Center·Phase 1/2·NCT06768905·30 enrolled

Malignancy1 trial

A Study of Chimeric Antigen Receptor T Cells Combined With Interventional Therapy in Advanced Liver Malignancy

Unknown status·SShanghai GeneChem Co., Ltd.·Phase 1/2·NCT02959151·20 enrolled

Acute Myeloid Leukemia1 trial

EX02 CAR-T Cells for Relapsed and Refractory Acute Myeloid Leukemia

Recruiting·ZZhimin Zhai·Phase 1·NCT06642025·9 enrolled

Hepatocellular Carcinoma1 trial

Phase I Study of GPC3 Targeted CAR-T Cell Therapy in Advanced GPC3 Expressing Solid Tumor Malignancies

Recruiting·NNational Cancer Institute (NCI)·Phase 1·NCT05003895·38 enrolled

Sources

References

[1]
ClinicalTrials.gov — 13 trial records for CAR-T cell. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — CAR-T cell compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for CAR-T cell. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — PersonGen BioTherapeutics (Suzhou) Co., Ltd. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Cell therapy[2]
Highest Phase: Phase 2[1]
Company: PPersonGen BioTherapeutics (Suzhou) Co., Ltd.

CAR-T cell

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2027

Q4 2027

Q2 2028

Trials by Indication[1]

Autoimmune Disease3 trials

Malignancies2 trials

Systemic Lupus Erythematosus1 trial

B-cell acute lymphoblastic leukemia1 trial

Nasopharyngeal Carcinoma1 trial

Lymphoblastic Lymphoma1 trial

Diffuse Large B-Cell Lymphoma1 trial

Malignancy1 trial

Acute Myeloid Leukemia1 trial

Hepatocellular Carcinoma1 trial

References

Drug Info

Quick Facts

Related News